Groupe Bruxelles Lambert (GBLB) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
5 Jun, 2025Executive summary
Governance strengthened with Johannes Huth as Managing Director and Ian Gallienne as Chairman, supporting strategic trajectory.
Strategic focus on generating €7bn resources for private asset investments and shareholder returns over 2024-2027, with nearly half of planned disposals completed.
Dividend per share increased by 82% to €5.00, yielding 7.6%, and 5.2m shares cancelled, reducing shares outstanding to 133.2m.
Enhanced shareholder returns via increased dividend, ongoing share buybacks, and robust liquidity profile.
Portfolio rotation continues, with significant disposals (adidas, SGS) and reinvestment in private assets.
Financial highlights
Q1 2025 cash earnings: €101m, down from €149m in Q1 2024, mainly due to lower dividends and higher interest expenses.
Consolidated net result: €94m in Q1 2025, compared to €194m in Q1 2024.
NAV per share at March 31, 2025: €111.17; €112.82 pro forma for share cancellations.
Liquidity profile remains strong at €5.6bn; LTV at 0.0%, lowest since 2017.
Market capitalization: €9.5bn, up 4% from December 2024; discount to NAV narrowed to 38.1%.
Outlook and guidance
Committed to double-digit total shareholder return (TSR) per annum through 2027, driven by NAV per share growth and increased distributions.
Dividend per share raised to €5.00 for 2024, payable in 2025, with a 7.6% yield based on year-end 2024 share price.
Ongoing opportunistic share buybacks, with a new €500m program approved and €110m completed in Q1 2025.
Committed to executing €5bn of disposals from 2024–2027, with nearly half already completed.
Portfolio companies, such as SGS, Pernod Ricard, and adidas, confirmed or reiterated positive 2025 outlooks, including organic growth and margin expansion.
Latest events from Groupe Bruxelles Lambert
- NAV per share up 3.8%, €1.1bn capital gains, €5.00 dividend, and double-digit TSR targeted.GBLB
Q3 2024 & Strategy Update16 Jan 2026 - Zero net debt, leadership change, 80% dividend hike, and strategic pivot to private assets.GBLB
AGM 202529 Nov 2025 - Portfolio simplification, strong healthcare growth, and enhanced shareholder returns marked the period.GBLB
Q3 20257 Nov 2025 - Record dividend, €0.8bn disposals, and private asset growth drove robust shareholder returns.GBLB
Q2 20258 Sep 2025 - GBL achieved meaningful growth in H1 2024, raising its dividend and strengthening its portfolio.GBLB
Investor Presentation13 Jun 2025 - NAV per share remained strong as asset rotation and dividend growth drove performance.GBLB
Q2 202413 Jun 2025 - 82% dividend hike and private asset growth drive mid-term value creation and TSR.GBLB
Q4 20245 Jun 2025